Latest news with #DiscMedicine
Yahoo
11-07-2025
- Business
- Yahoo
Morgan Stanley Assumes Coverage of Disc Medicine (IRON) With $85 PT
Disc Medicine, Inc. (NASDAQ:IRON) is one of the Morgan Stanley assumed coverage of the company's stock with an 'Overweight' rating and a price objective of $85, as reported by The Fly. The research firm highlighted bitopertin's potential to reach the market faster than was earlier expected via an accelerated approval process. Furthermore, the firm expects additional upside potential from Disc Medicine, Inc. (NASDAQ:IRON)'s pipeline programs in anemia, particularly highlighting DISC-0974. A scientist in a laboratory setting examining a sample of blood with a microscope. The company has initiated APOLLO, which is a confirmatory clinical trial of bitopertin in adults and adolescents with EPP. Disc Medicine, Inc. (NASDAQ:IRON) stated that 2025 is off to a robust start as it continues to make operational progress throughout the portfolio. The company opines that bitopertin has the potential to be a life-altering therapy. Furthermore, Disc Medicine, Inc. (NASDAQ:IRON) highlighted that, due to a strong financial foundation that offers a cash runway into 2028, it remains well-placed to progress the commercial preparation efforts for bitopertin and the development of the rest of its pipeline. The company had cash, cash equivalents, and marketable securities of $694.7 million as of March 31, 2025. While we acknowledge the potential of IRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-06-2025
- Business
- Yahoo
Leerink Partners Reiterates a Buy Rating on Disc Medicine (IRON) With an $85 Price Target
Disc Medicine, Inc. (NASDAQ:IRON) is one of the 13 Small Cap Stocks Analysts Are Bullish On. In a report released on June 16, Thomas Smith from Leerink Partners maintained a Buy rating on Disc Medicine, Inc. (NASDAQ:IRON) with a price target of $85.00. The analyst based the rating on the company's positive developments in its hematology-focused pipeline. A scientist in a laboratory setting examining a sample of blood with a microscope. Smith stated that Disc Medicine, Inc. (NASDAQ:IRON) is set to submit a New Drug Application for bitopertin, an oral GlyT1 inhibitor, that is anticipated to leverage an accelerated approval pathway. The HELIOS long-term extension study reported positive initial data supporting this progress, as it suggested improvements in live function, sustained reductions in PPIX, and a clean safety profile. Disc Medicine, Inc. (NASDAQ:IRON) is also participating in ongoing trials, such as the Phase 2 RALLY-MF trial and the Phase 1b MF anemia trial, which have shown positive results with improved biomarker responses. The analyst considers this another positive factor supporting the buy rating. Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes treatments for hematologic diseases. While we acknowledge the potential of IRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
24-06-2025
- Business
- Yahoo
Leerink Partners Reiterates a Buy Rating on Disc Medicine (IRON) With an $85 Price Target
Disc Medicine, Inc. (NASDAQ:IRON) is one of the 13 Small Cap Stocks Analysts Are Bullish On. In a report released on June 16, Thomas Smith from Leerink Partners maintained a Buy rating on Disc Medicine, Inc. (NASDAQ:IRON) with a price target of $85.00. The analyst based the rating on the company's positive developments in its hematology-focused pipeline. A scientist in a laboratory setting examining a sample of blood with a microscope. Smith stated that Disc Medicine, Inc. (NASDAQ:IRON) is set to submit a New Drug Application for bitopertin, an oral GlyT1 inhibitor, that is anticipated to leverage an accelerated approval pathway. The HELIOS long-term extension study reported positive initial data supporting this progress, as it suggested improvements in live function, sustained reductions in PPIX, and a clean safety profile. Disc Medicine, Inc. (NASDAQ:IRON) is also participating in ongoing trials, such as the Phase 2 RALLY-MF trial and the Phase 1b MF anemia trial, which have shown positive results with improved biomarker responses. The analyst considers this another positive factor supporting the buy rating. Disc Medicine, Inc. (NASDAQ:IRON) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes treatments for hematologic diseases. While we acknowledge the potential of IRON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Business Insider
17-06-2025
- Business
- Business Insider
Analysts' Top Healthcare Picks: Nurix Therapeutics (NRIX), Disc Medicine (IRON)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nurix Therapeutics (NRIX – Research Report), Disc Medicine (IRON – Research Report) and Silence Therapeutics (SLN – Research Report) with bullish sentiments. Confident Investing Starts Here: Nurix Therapeutics (NRIX) In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Nurix Therapeutics, with a price target of $25.00. The company's shares closed last Thursday at $11.96, close to its 52-week low of $11.90. According to Archila is a 5-star analyst with an average return of 9.3% and a 50.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, Monte Rosa Therapeutics, and Apellis Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nurix Therapeutics with a $29.43 average price target, a 137.9% upside from current levels. In a report issued on June 2, Needham also maintained a Buy rating on the stock with a $27.00 price target. Disc Medicine (IRON) In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Disc Medicine. The company's shares closed last Thursday at $52.71. According to Bancroft is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.9% and a 37.1% success rate. Bancroft covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Protagonist Therapeutics, and Whitehawk Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Disc Medicine with a $99.10 average price target, implying a 95.9% upside from current levels. In a report issued on June 10, Raymond James also initiated coverage with a Buy rating on the stock with a $89.00 price target. Silence Therapeutics (SLN) In a report released today, Myles Minter from William Blair reiterated a Buy rating on Silence Therapeutics. The company's shares closed last Thursday at $5.59, close to its 52-week low of $3.19. According to Minter is a 4-star analyst with an average return of 6.9% and a 47.1% success rate. Minter covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Neumora Therapeutics, Inc., and Entrada Therapeutics Inc.
Yahoo
17-06-2025
- Business
- Yahoo
Raymond James bullish on biotech firms on favorable valuation
-- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid 'suppressed valuations.' Recent market weakness has created an attractive setup for investors willing to take on risk in high potential clinical-stage names, with upcoming catalysts likely to re-rate shares across several of its covered companies. Raymond James initiated Avidity Biosciences at Strong Buy with a $65 price target, calling its AOC (antibody oligonucleotide conjugate) platform 'ready for prime time.' The firm sees high conviction in Avidity's lead candidate del-zota for Duchenne muscular dystrophy and highlighted significant upside from potential first-mover drugs targeting DM1 and FSHD, both of which have large market opportunities. Disc Medicine was also rated Strong Buy, with an $89 target. Raymond James expects upside from bitopertin, its lead program in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and said the broader pipeline provides 'two free call options.' For Dyne Therapeutics, the firm assigned an Outperform rating with a $37 target, arguing that the market is undervaluing DYNE-101, its DM1 program. It believes regulatory clarity could lift sentiment. Tectonic Therapeutic, rated Outperform with a $76 price target, was described as having one of the most attractive risk/reward profiles in the firm's coverage. Its TX45 asset is being tested in pulmonary hypertension and has shown early clinical activity. Wave Life Sciences was rated Outperform with a $14 target, with Raymond James citing favorable risk/reward into key Phase 2 data updates in obesity and alpha-1 antitrypsin deficiency in the second half of 2025. Related articles Raymond James bullish on biotech firms on favorable valuation U.S. private equity firm Advent in exclusive talks for Reckitt's home unit BCA flags risks for BOTZ ETF as robotization pace may disappoint Sign in to access your portfolio
